Bavencio (Avelumab), Inlyta (Axitinib) Combination Approved for Advanced Renal Cell Carcinoma by FDA

Approval marks the first anti-PD-L1 therapy combination for RCC.

Source: CancerNetwork - May 15, 2019 Category: Cancer & Oncology Authors: Drew Boxler Source Type: news